<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">Against this background, CQ was evaluated in SARS CoV-2 infection and showed very good 
 <italic>inÂ vitro</italic> efficacy [
 <xref rid="bib12" ref-type="bibr">12</xref>]. The clinical evidence was recently published from France. In this study of 36 patients, 20 patients were treated with hydroxychloroquine (HCQ), out of which 6 also received azithromycin, and 16 patients served as controls. At day 6 post treatment the proportion of patients who were negative for SARS CoV-2 was 100%, 57% and 12.%% for those treated with HCQ and azithromycin combination, HCQ only and controls, respectively [
 <xref rid="bib13" ref-type="bibr">13</xref>].Though this is a small study, the results are very encouraging. Further, a report from China showed good efficacy of CQ in patients with COVID-19, though there was no access to detailed data [
 <xref rid="bib14" ref-type="bibr">14</xref>].Concurrently, several trials are planned to study its role in prevention and treatment of COVID-19 and at present, it is difficult to make recommendations based on these preliminary data.
</p>
